Galenea Corp. has entered a strategic collaboration with Eisai Co. Ltd., under which Galenea will apply its synaptic transmission platform technology to address synaptic dysfunction in neurodegenerative diseases. The collaboration aims discover and develop novel therapeutics for neurodegeneration mediated by a disease-specific protein. Eisai will make an undisclosed upfront payment and milestone payments throughout the program.
Galenea’s approach addresses disease mechanism using MANTRA, a high throughput screening system for synaptic function, predictive animal models using integrated behavioral assessment, and EEG measures and clinical biomarkers using translational EEG measures elicited by behavioral tasks in the clinic.
“Eisai has one of the most successful neuroscience franchises today, and has made a clear commitment to innovation and discovery. This collaboration, which is focused on a single, highly implicated target in neurodegeneration, has been crafted to take advantage of our unique approach,” said Mark Benjamin, Galenea’s president and chief executive officer. “We are thrilled to be working with Eisai, and we see enormous potential in this program and partnership.”